GEP-NET

Clinical trials for GEP-NET explained in plain language.

Never miss a new study

Get alerted when new GEP-NET trials appear

Sign up with your email to follow new studies for GEP-NET, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Terminated 1

New Long-Acting drug for rare hormone tumors tested, but study stopped early

Disease control Terminated

This early-stage study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the study was terminated. The goal was to measure…

Matched conditions: GEP-NET

Phase: PHASE1 • Sponsor: Debiopharm International SA • Aim: Disease control

Last updated May 06, 2026 16:01 UTC

GEP-NET

Get alerted when new GEP-NET trials appear

New Long-Acting drug for rare hormone tumors tested, but study stopped early